"Digoxin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666)
| Descriptor ID |
D004077
|
| MeSH Number(s) |
D04.210.500.155.580.130.500.436 D04.210.500.155.580.130.688 D09.408.180.261.436
|
| Concept/Terms |
Digoxine Nativelle- Digoxine Nativelle
- Nativelle, Digoxine
- Hemigoxine Nativelle
- Nativelle, Hemigoxine
Lanoxin- Lanoxin
- Lanoxin-PG
- Lanoxin PG
- Lenoxin
|
Below are MeSH descriptors whose meaning is more general than "Digoxin".
Below are MeSH descriptors whose meaning is more specific than "Digoxin".
This graph shows the total number of publications written about "Digoxin" by people in this website by year, and whether "Digoxin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 4 | 3 | 7 |
| 2018 | 9 | 2 | 11 |
| 2019 | 1 | 2 | 3 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Digoxin" by people in Profiles.
-
Covid-19 and development of heart failure: mystery and truth. Naunyn Schmiedebergs Arch Pharmacol. 2021 10; 394(10):2013-2021.
-
Role for digoxin in patients hospitalized with COVID-19 and atrial arrhythmias. J Cardiovasc Electrophysiol. 2021 03; 32(3):880-881.
-
Atrial fibrillation and flutter in patients hospitalized for COVID-19: The challenging role of digoxin. J Cardiovasc Electrophysiol. 2021 03; 32(3):878-879.
-
A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Signal Transduct Target Ther. 2020 10 03; 5(1):218.
-
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Sci Rep. 2020 10 01; 10(1):16200.
-
Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol. 2019 08 06; 74(5):617-627.
-
Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum: Phenotyping, and Prognostic and Therapeutic Implications. JACC Heart Fail. 2019 06; 7(6):505-515.
-
A prospective study of the clinical outcomes and prognosis associated with comorbid COPD in the atrial fibrillation population. Int J Chron Obstruct Pulmon Dis. 2019; 14:371-380.
-
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. Eur J Heart Fail. 2019 May; 21(5):577-587.
-
Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. Am J Cardiol. 2019 01 01; 123(1):69-74.